Sanders KM, Ward SM, Koh SD
PubMed, Kronenberg, F., and G
Rational design is not widely used, except for P5, PRG-RADA16, and RK81 QTY [97,130]
Periodontal infections are more severe and chronic and are fueled by a dysregulated neutrophil response and pro-inflammatory gingival milieu, and can further potentiate insulin resistance (60)
Prophecys expertise area covers products, services, latest trends, developments, market growth factors, and challenges along with market forecasts in various business areas such as Healthcare, Pharmaceutical, Biotechnology, Information Technology (IT), Automotive, Industrial, Chemical, Agriculture, Food and Beverage, Energy, and Oil and Gas
What we know: GI side effects are common but typically improve after 36 months No deaths or major safety signals through 80104 weeks across two large trials Metabolic improvements (glucose, blood pressure, lipids) are substantial and sustained Discontinuation rate: 11.3% in general obesity population (TRIUMPH-1) better than initially feared from TRIUMPH-4's 18.2% 104-week extension shows continued weight loss to 30.3% no plateau at 80 weeks What we don't know: Full 2-year safety dataset (pending publication) Whether dysesthesia resolves or persists long-term Cardiovascular outcomes (trial ongoing) Weight regain trajectory after stopping Very rare adverse events requiring broader use to detect The bottom line: Retatrutide offers superior weight loss compared to existing medications and TRIUMPH-1's 11.3% discontinuation rate suggests the tolerability picture is better than TRIUMPH-4's osteoarthritis cohort implied
